Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 18/20 | 0.78 |
| ▸ | CHRNA3 | P32297 | 18/20 | 0.78 |
| ▸ | CHRNA4 | P43681 | 18/20 | 0.78 |
| ▸ | CHRNB3 | Q05901 | 16/20 | 0.78 |
| ▸ | CHRNA6 | Q15825 | 16/20 | 0.78 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.50 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12356574 | 1.00 | CHRNB2 (0.78) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| Hydrochloric Acid SCHEMBL1902519 | 0.98 | CHRNB2 (0.75) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| Hydrochloric Acid SCHEMBL745115 | 0.98 | CHRNB2 (0.75) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL1978267 | 0.88 | CHRNB2 (1.00) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL14070518 | 0.82 | CHRNB2 (0.72) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL19948600 | 0.78 | CHRNB2 (0.61) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL1896388 | 0.78 | CHRNB2 (0.61) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL1404444 | 0.78 | CHRNB2 (0.61) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL1008491 | 0.78 | CHRNB2 (0.61) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| Hydrochloric Acid SCHEMBL741789 | 0.76 | CHRNB2 (0.59) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022269508-A1 | PYRAZOLYL DERIVATIVES AS INHIBITORS OF THE KRAS MUTANT PROTEIN | NOVARTIS AG (CH) | 2022-12-29 | — | — | WO | disclosed |
| WO-2021062246-A1 | CRF RECEPTOR ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. (US) | 2021-04-01 | — | — | WO | disclosed |
| US-9662339-B2 | Benzodioxane inhibitors of leukotriene production for combination therapy | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-05-30 | — | — | US | disclosed |
| US-9662339-B2 | Benzodioxane inhibitors of leukotriene production for combination therapy | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-05-30 | — | — | US | disclosed |
| EP-2822941-B1 | BENZODIOXANES IN COMBINATION WITH STATINS FOR INHIBITING LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INT (DE) | 2017-05-10 | — | — | EP | disclosed |
| EP-2822942-B1 | BENZODIOXANES FOR INHIBITING LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INT (DE) | 2017-05-10 | — | — | EP | disclosed |
| EP-2885285-B1 | PYRAZOLE DRIVATIVES WHICH INHIBIT LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INT (DE) | 2016-10-19 | — | — | EP | disclosed |
| US-9403830-B2 | Inhibitors of leukotriene production | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-08-02 | — | — | US | disclosed |
| US-9403830-B2 | Inhibitors of leukotriene production | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-08-02 | — | — | US | disclosed |
| US-8946203-B2 | Benzodioxane inhibitors of leukotriene production | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-02-03 | — | — | US | disclosed |
| EP-2430019-B1 | COMPOUNDS WITH TWO FUSED BICYCLIC HETEROARYL MOIETIES AS MODULATORS OF LEUKOTRIENE A4 HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2013-09-18 | — | — | EP | disclosed |
| US-20130236468-A1 | BENZODIOXANE INHIBITORS OF LEUKOTRIENE PRODUCTION FOR COMBINATION THERAPY | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-09-12 | — | — | US | disclosed |
| US-20130236468-A1 | BENZODIOXANE INHIBITORS OF LEUKOTRIENE PRODUCTION FOR COMBINATION THERAPY | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-09-12 | — | — | US | disclosed |
| WO-2013134226-A1 | BENZODIOXANES FOR INHIBITING LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-09-12 | — | — | WO | disclosed |
| WO-2013131901-A1 | BENZODIOXANES IN COMBINATION WITH OTHER ACTIVES FOR INHIBITING LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-09-12 | — | — | WO | disclosed |
| US-8399465-B2 | Compounds with two fused bicyclic heteroaryl moieties as modulators of leukotriene A4 hydrolase | JANSSEN PHARMACEUTICA NV (BE) | 2013-03-19 | — | — | US | disclosed |
| EP-2430019-A1 | COMPOUNDS WITH TWO FUSED BICYCLIC HETEROARYL MOIETIES AS MODULATORS OF LEUKOTRIENE A4 HYDROLASE | Janssen Pharmaceutica, N.V. (BE) | 2012-03-21 | — | — | EP | disclosed |
| WO-2010132599-A1 | COMPOUNDS WITH TWO FUSED BICYCLIC HETEROARYL MOIETIES AS MODULATORS OF LEUKOTRIENE A4 HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-18 | — | — | WO | disclosed |
| US-20100292208-A1 | COMPOUNDS WITH TWO FUSED BICYCLIC HETEROARYL MOIETIES AS MODULATORS OF LEUKOTRIENE A4 HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-18 | — | — | US | disclosed |
| EP-0746560-A1 | 3,8-DIAZABICYCLO 3.2.1]OCTANE DERIVATIVES HAVING ANALGESIC ACTIVITY | RIACE ESTABLISHMENT (LI) | 1996-12-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292208-A1 | COMPOUNDS WITH TWO FUSED BICYCLIC HETEROARYL MOIETIES AS MODULATORS OF LEUKOTRIENE A4 HYDROLASE | LTA4H, LTC4S, LTB4R | CHRNB2 2508/4885CHRNA3 2160/4885CHRNA4 924/4885 |
| US-20130236468-A1 | BENZODIOXANE INHIBITORS OF LEUKOTRIENE PRODUCTION FOR COMBINATION THERAPY | LTB4R, LTB4R2, LTC4S | CHRNB2 2911/4885CHRNA3 2531/4885CHRNA4 2533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.